|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on January 9, 2003; DOI 10.1182/blood-2002-04-1237.
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Veterans Administration, Lakeside
Division, Chicago Health Care System, Chicago, IL; the Department of
Medicine, Northwestern University Medical School, Chicago, IL; and the
Department of Oral Sciences, University of Minnesota School of
Dentistry, Minneapolis, MN.
Angiogenesis plays an important role in a variety of
pathophysiologic processes, including tumor growth and rheumatoid
arthritis. We have previously shown that soluble E-selectin
(sE-selectin) is an important angiogenic mediator. However, the
mechanism by which sE-selectin mediates angiogenesis is still unknown.
In this study, we show that sE-selectin is a potent mediator of human dermal microvascular endothelial cell (HMVEC) chemotaxis, which is
predominantly mediated through the Src and the phosphatidylinositiol 3-kinase (PI3K) pathways. Further, sE-selectin induced a 2.2-fold increase in HMVEC tube formation in the Matrigel in vitro assay. HMVECs pretreated with the Src inhibitor (PP2) and the PI3K
inhibitor (LY294002) or transfected with Src antisense oligonucleotides or Akt dominant-negative mutants significantly inhibited
sE-selectin-mediated HMVEC tube formation. In contrast, HMVECs
transfected with an extracellular signal-related kinase 1/2
(ERK1/2) mutant or pretreated with the mitogen-activated
protein kinase (MAPK) inhibitor PD98059 failed to show
sE-selectin-mediated HMVEC tube formation. Similarly, in the
Matrigel-plug in vivo assay, sE-selectin induced a 2.2-fold increase in
blood vessel formation, which was significantly inhibited by PP2 and
LY294002 but not by PD98059. sE-selectin induced a marked
increase in Src, ERK1/2, and PI3K phosphorylation. PI3K and ERK1/2
phosphorylation was significantly inhibited by PP2, thereby suggesting
that both of these pathways may be activated via Src kinase. Even
though the ERK1/2 pathway was activated by sE-selectin in HMVECs, it
seems not to be essential for sE-selectin-mediated angiogenesis. Taken
together, our data clearly show that sE-selectin-induced angiogenesis
is predominantly mediated through the Src-PI3K pathway.
(Blood. 2003;101:3960-3968) Angiogenesis, or new blood vessel formation, is a
complex process that involves endothelial cell proliferation and
migration, followed by capillary tube formation. Each stage in this
process can be modulated by a number of factors present in normal or
pathologic conditions. Vascular endothelial growth factor (VEGF) is one
of the most studied factors that mediates angiogenesis through Src family kinases and phosphatidylinositiol 3-kinase (PI3K)
pathways.1,2 Src kinases are activated by a variety of
growth factors and function downstream of receptor tyrosine
kinases.3,4 Eliceiri et al, showed that both VEGF and
fibroblast growth factor (FGF) stimulate Src activation in avian
endothelial cells.1 However, only VEGF-induced angiogenesis was inhibited by treatment with a retrovirus that encodes
Src-251, a dominant-interfering mutant of Src. Moreover, overexpression
of Src-251 in avian blood vessels induces apoptotic death, indicating
that VEGF-induced activation of Src is essential for endothelial cell
survival and angiogenesis. Src kinases, once activated, may in turn
activate downstream PI3K. PI3K has been implicated in a number of
cellular functions including cell adhesion, cell survival, and
angiogenesis.2,5 The serine-threonine kinase, Akt, is a
downstream target of PI3K. Cardone et al6 have shown
that Akt phosphorylation promotes cell survival by phosphorylating
Bcl-2/Bcl-XL agonist causing cell death (BAD), forkhead-related protein 1 (FKHR1), and caspase-9. Akt has also been
shown to play an important role in angiogenesis.2
E-selectin is a calcium-dependent lectin that mediates adhesive
interactions of circulating leukocytes with vascular endothelium during
normal and abnormal inflammatory conditions such as rheumatoid arthritis (RA) and atherosclerosis.7,8 E-selectin is a
single-chain 115-kDa glycoprotein with a lectinlike N terminal domain,
an epidermal growth factor (EGF)-like motif, and a variable number of
repeat units homologous to the consensus repeats of complement binding proteins.9 The lectin domain of E-selectin plays a major
role in ligand recognition and binds to sialyl Lex on
leukocytes as well as on endothelial cells.10-12
E-selectin is rapidly synthesized and expressed on activated
endothelial cells and is rapidly shed from the cellular surfaces on
cellular activation.7 Elevated levels of soluble
E-selectin (sE-selectin) have been found in patients with
vasculoproliferative disorders such as RA13 and tumor
growth.14,15 We have previously shown that sE-selectin is
a potent angiogenic mediator.16 Recently, we have shown
that sE-selectin mediates monocyte chemotaxis through the Src-
mitogen-activated protein kinase (MAPK) pathway.17 However, the signaling pathways by which sE-selectin mediates angiogenesis are still unknown.
In this study, we examined the signaling pathways by which sE-selectin
mediates angiogenesis. Our results suggest that sE-selectin mediates
its signal in HMVECs through the Src-PI3K pathway. Inhibition of Src, MAPK, and PI3K pathways with PP2, PD98059, and LY294002, respectively, significantly reduced sE-selectin-mediated HMVEC chemotaxis. Similarly, PP2 and LY294002 significantly inhibited Matrigel in vitro endothelial cell tube formation and Matrigel in vivo
blood vessel formation. However, PD98059 failed to significantly inhibit in vitro endothelial cell tube formation as well as in vivo
blood vessel formation. Taken together, these results suggest that
Src- and PI3K-dependent signaling pathways are major mediators of sE-selectin-induced angiogenesis.
Reagents
Cell culture, cell lysis, and immunoblotting
Plasmid constructions and transient transfections HMVECs were transiently transfected with 4 µg pcDNA3 plasmid containing the dominant-negative mutants of ERK1/2, Akt, p38 MAPK, or c-Jun (a gift from Dr Cun-Yu Wang, University of Michigan, Ann Arbor) using Lipofectin kits (Invitrogen) per the manufacturer's instructions. An empty pcDNA3 plasmid was used as a negative control and a pcDNA3 plasmid containing CAT was used to optimize transfection efficiency. At 72 hours after transfections, HMVECs were used in chemotaxis assays (or Matrigel in vitro HMVEC tube formation assays) or harvested for Western blotting.Preparation of oligonucleotides (ODNs) and lipofection of HMVECs The ODNs were synthesized and purified by the Northwestern University Biotechnology Laboratory and modified with phosphorothioate. Sequences of the c-Src ODNs used in the study are as follows: antisense, GGG CTT GCT CTT GCT GCT CCC CAT; and sense, ATG GGG AGC AGC AAG AGC AAG CCC.18 HMVECs were transiently transfected with sense and antisense ODNs as described earlier.18 At 16 hours after transfection, HMVECs were used for chemotaxis assays (or Matrigel in vitro HMVEC tube formation assays) or harvested for Western blotting.PI3K assay HMVECs (2 × 105 cells/well) were plated in 6-well plates in EBM containing bullet and 10% FBS. Once the cells were 80% to 90% confluent, they were further incubated in EBM containing reduced serum (2% FBS) for 2 hours. HMVECs were then stimulated with sE-selectin (50 nM) for 15 minutes at 37°C. At the end of the incubation, cell lysate was prepared. For inhibitor studies, HMVECs were pretreated with PP2 (10 µM) for 2 hours prior to stimulation with sE-selectin. PP2 was also present during HMVEC stimulation with sE-selectin. The protein content of each sample was quantitated using a bicinchoninic acid (BCA) protein assay kit and normalized according to the protein concentration. Of each sample, 500 µg in 500 µL lysis buffer was incubated with 5 µL rabbit anti-PI3K antibody overnight at 4°C with continuous shaking. Protein A agarose conjugate (60 µL; 50% slurry in phosphate-buffered saline [PBS]) was added to each sample and further incubated for one hour at 4°C. The immunoprecipitates were collected by centrifuging at 14 000g for 10 seconds. The immunoprecipitates were then washed 3 times with buffer A (137 mM NaCl; 20 mM Tris-HCl, pH 7.4; 1 mM CaCl2; 1 mM MgCl2; and 0.1 mM sodium orthovanadate) containing 1% nonionic detergent IGEPAL CA-630, followed by 3 washes with buffer B (0.1 M Tris-HCl, pH 7.4; 5 mM LiCl; and 0.1 mM sodium orthovanadate) and 3 washes with TNE (10 mM Tris-HCl, pH 7.4; 150 mM NaCl; and 5 mM EDTA) containing 0.1 mM sodium orthovanadate. The last wash was removed as completely as possible. To each sample, the following reagents were added sequentially: 50 µL TNE, 10 µL (20 µg) phosphatidylinositol (PI, in 10 mM Tris-HCl, pH 7.4, containing 1 mM EGTA), and 10 µL 100 mM MgCl2. The PI reaction was initiated with the addition of 5 µL [ -32P] ATP. The reaction
mixture was incubated at 37°C for 15 minutes with continuous
agitation. The reaction was stopped by the addition of 20 µL 6 N HCl.
Radiolabeled lipid was extracted from the reaction sample by adding 160 µL CH3Cl/MeOH (1:1), vortexing, and then separating the
organic and aqueous phases by centrifugation for 10 minutes at
14 000g. Radiolabeled lipid (50 µL) containing
the lower organic phase was spotted onto oxalate-treated thin layer chromatography (TLC) plates (Fisher Scientific, Pittsburgh, PA) and
developed in
CHCl3/MeOH/H2O/NH4OH
(60:47:11.3:2). The TLC plates were dried and autoradiographed.
HMVEC chemotaxis HMVECs (3.75 × 104 cells/25 mL EBM and 0.1% FBS) were placed in the bottom wells of a 48-well Boyden chemotaxis chamber (NeuroProbe, Cabin John, MD) with gelatin-coated polycarbonate membranes (8-µM pore size; Nucleopore, Pleasanton, CA).16 The chambers were inverted and incubated in a humidified incubator with 5% CO2/95% air at 37°C for 2 hours, allowing endothelial cell attachment to the membrane. The chambers were inverted, and the test substances, PBS or positive control bFGF (60 nM) in PBS, were added, and the chamber was further incubated for 2 hours at 37°C. In the inhibitor studies, HMVECs were pretreated with the respective inhibitor (10 µM PP2, LY294002, or PD98059; or 50 ng/mL PT) for 2 hours, and inhibitors were present in the lower chamber along with HMVECs during the chemotaxis assay. The membranes were then removed, fixed in methanol for 1 minute, and stained with Diff-Quik (Dade Behring, Newark, DE). The data are expressed as the number of cells migrating through the membrane per well (the sum of 3 high-power × 40 fields per well, averaged for each quadruplicate well).Matrigel in vitro HMVEC tube formation assay The Matrigel in vitro assay was used to examine HMVEC tube formation in response to sE-selectin. Matrigel was plated in 8-well chamber slides after thawing on ice and allowed to polymerize at 37°C for 30 to 60 minutes. HMVECs (400 µL; 4 × 104 cells/mL in media 199 containing 2% FBS and 200 mg/mL endothelial cell growth supplement [Becton Dickinson]) was added to each chamber and treated with bFGF (vehicle control) or sE-selectin with or without the respective inhibitor. The chamber slides were then incubated for 16 to 18 hours at 37°C in 5% CO2 humidified atmosphere. Culture media were aspirated off the Matrigel surface, and the cells were fixed with methanol and stained with Diff-Quick Solution II. Each chamber was photographed using a Polaroid Microcam camera (Carl Zeiss, Jena, Germany) at × 22 magnification. The number of tubes formed was quantitated as previously described.19 Briefly, a connecting branch between 2 discreet endothelial cells was counted as one "tube."Matrigel-plug angiogenesis in vivo assay To examine the effect of sE-selectin on angiogenesis in vivo a Matrigel-plug assay was used.20,21 C57/BL6 mice were anesthetized by Metofane inhalation. Each mouse was shaved on its ventral aspect and given a subcutaneous injection of sterile Matrigel (500 mL/injection) with a 27-gauge needle. Matrigel containing PBS served as the negative control; Matrigel containing bFGF (1 ng/mL) served as the positive control; and Matrigel with sE-selectin (100 nM) was the test substance. In the inhibitor study, 20 µM respective inhibitor (PP2, LY294002, or PD98059) was added along with sE-selectin in the Matrigel before it was injected. After 7 to 10 days, the mice were killed by Metofane inhalation and cervical dislocation. The Matrigel plugs were then carefully dissected out, with removal of any surrounding connective tissue, and then analyzed by hemoglobin measurement or by histology.22,23 For histologic analysis, 3 plugs from each group were embedded in paraffin for tissue sectioning and staining.Hemoglobin determination in Matrigel plugs. Hemoglobin levels in the Matrigel plug correlate with blood vessel growth.19 The Matrigel plugs dissected from the mice were carefully stripped of any remaining peritoneum. The plugs were weighed and homogenized for 5 to 10 minutes on ice. Supernatant or standard (50 µL) was added to a 96-well plate in duplicate, followed by 50 µL tetramethylbenzidine. The plate was allowed to develop at room temperature for 15 to 20 minutes with gentle shaking, and the reaction was stopped by adding 150 µL 2N H2SO4. Absorbance was read at 450 nm, and hemoglobin levels were normalized by the weight of the plugs. Masson trichrome staining of Matrigel plugs. Using Masson trichrome straining, 5-mm sections were deparaffinized and stained.19 In brief, sections were hydrated in distilled water followed by incubation with Bouin solution for one hour at 56°C, washing in water, incubation with Weigert iron solution for 7 minutes, washing with water, and incubation with Biebrich scarlet-acid fuchsin solution for 2 minutes. Sections were then rinsed, incubated in phosphomolybdic-phosphotungstic acid solution for 10 minutes, dipped in aniline blue solution for 5 minutes, rinsed, dipped in glacial acetic acid solution for 3 to 5 minutes, and dehydrated in 2 changes of 95% alcohol, 100% alcohol, and 100% xylene. The slides were mounted with Cytoseal 60 (Stephens Scientific, Kalamazoo, MI). Statistical analysis Data were analyzed using Student t test, and P values less than .05 were considered significant.
sE-selectin mediates HMVEC chemotaxis through the Src and PI3K pathways We have previously shown that sE-selectin is a potent angiogenic mediator.16 To examine the signaling cascade by which sE-selectin mediates angiogenesis, we performed HMVEC chemotaxis assays, a facet of the angiogenic response, in 48-well modified Boyden chambers. sE-selectin induced a dose-dependent increase in HMVEC chemotaxis, reaching significance at 1 nM to 100 nM (P < .05, Figure 1A), compared with negative control PBS. bFGF was used as positive control in all the assays. To further study the role of different signaling pathways that may be involved in sE-selectin-mediated HMVEC chemotaxis, HMVECs were pretreated with the respective signaling inhibitor or combination of Src kinase inhibitor (PP2, 10 µM), PI3K inhibitor (LY294002, 10 µM), MAPK inhibitor (PD98059, 10 µM), or G-protein inhibitor (PT, 50 ng/mL) for 2 hours prior to performing the chemotaxis assays. The Src inhibitor (PP2) was most effective in inhibiting sE-selectin-mediated HMVEC chemotaxis (37%), whereas the MAPK inhibitor (PD98059), PI3K inhibitor (LY294002), and G-protein inhibitor (PT) showed 20%, 34%, and 9% inhibition, respectively (Figure 1B). HMVECs pretreated with the combination of PP2 and PD98059 showed 76% inhibition of chemotaxis, which was further enhanced by the combination of PP2 and LY294002 (79%) or the combination of PP2, PD98059, and LY294002 (87%). However, the combination of PD98059 and LY294002 showed 47% sE-selectin-mediated HMVEC chemotaxis inhibition.
To further corroborate the results obtained in the HMVEC chemotaxis
studies using signaling inhibitors, we performed a similar assay using
HMVECs transiently transfected with dominant-negative mutants of ERK1/2
and Akt or HMVECs transiently transfected with c-Src antisense and
sense ODNs. A pcDNA3 plasmid with no insert was used as control for the
mutant studies. HMVECs transiently transfected with plasmids with no
insert showed significantly more chemotaxis in response to both
sE-selectin and positive control bFGF (Figure
2A). HMVECs transfected with the Akt
mutants showed significantly less (55%) sE-selectin-mediated HMVEC
chemotaxis, whereas HMVECs transfected with the ERK1/2 mutants did not
show a significant inhibition (14%). HMVECs transfected with Src
antisense ODNs showed significant inhibition (53%) of
sE-selectin-mediated chemotaxis compared with HMVECs transfected with
sense ODNs (Figure 2B). These results from HMVEC chemotaxis assay using
signaling inhibitors, dominant-negative mutants, and sense and
antisense ODNs suggest that sE-selectin may be mediating HMVEC
chemotaxis predominantly through the Src and PI3K pathways and
partially through the MAPK pathway.
Signaling cascade mediated by sE-selectin in HMVECs We next examined the signaling pathways involved in sE-selectin-stimulated HMVECs. sE-selectin induced protein tyrosine phosphorylation of several proteins in the molecular-weight range of 140 to 150, 130 to 140, 50 to 65, and 30 to 40 kDa (data not shown). As the predominant band was observed in the molecular-weight range of Src kinase ( 60 kDa), we were interested to determine whether Src
family kinases were activated in HMVECs upon stimulation with sE-selectin. We performed a time-course study of Src kinase activation followed by Src inhibition using the Src inhibitor PP2. sE-selectin induced a marked increase in Src phosphorylation at 10, 20, and 30 minutes (Figure 3). Pretreatment of
HMVECs with PP2 showed substantial inhibition of Src phosphorylation at
20 and 30 minutes. Equal amounts of protein samples were loaded in each
lane, as confirmed by stripping the blots and reprobing with rabbit
antihuman total Src antibody. We next examined whether sE-selectin
could also activate the ERK1/2 and the p38 MAPK pathways in HMVECs. sE-selectin induced a time-dependent increase in phosphorylation of
ERK1/2, which peaked at 30 minutes (Figure
4). However, sE-selectin failed to
activate p38 MAPK in HMVECs (data not shown). sE-selectin-induced ERK1/2 phosphorylation was significantly inhibited by the pretreatment of HMVECs with PP2, suggesting that Src lies upstream of ERK1/2 in
sE-selectin-mediated endothelial cell signaling (Figure 4).
Because the PI3K/Akt pathway is known to play an important role in
angiogenesis, we also examined whether the PI3K/Akt pathway is
activated in sE-selectin-stimulated HMVECs.2,24 HMVECs stimulated with sE-selectin showed a marked increased in PI and Akt
phosphorylation (Figure 5), thereby
indicating that sE-selectin, in addition to activating Src and ERK1/2,
also activates the PI3K/Akt pathway in HMVECs. Next, we examined
whether sE-selectin-induced activation of PI3K in HMVECs was mediated
via Src kinases. To study this, we first pretreated HMVECs with the Src
inhibitor PP2 (10 µM) for 2 hours prior to preparing the cell lysate
for both the PI3K assay and the Akt phosphorylation studies.
Pretreatment of HMVECs with PP2 substantially inhibited
sE-selectin-mediated PI3K activation as observed by PI3K assay and Akt
phosphorylation studies (Figure 5). To further examine whether there
was any cross talk between the PI3K/Akt and ERK1/2 pathways in
sE-selectin-stimulated endothelial cells, HMVECs were pretreated with
PP2, PD98059, or LY294002 prior to stimulation with sE-selectin. The
Src inhibitor PP2, as observed earlier, inhibited both Akt and ERK1/2
activation (Figure 6A). The PI3K
inhibitor (LY294002) and the ERK1/2 inhibitor (PD98059) failed to show
ERK1/2 and Akt inhibition, respectively. Similarly, HMVECs transfected
with the ERK1/2 mutants showed inhibition of
sE-selectin-induced ERK1/2 phosphorylation, but not of Akt phosphorylation. HMVECs transfected with the Akt mutants showed inhibition of Akt phosphorylation but not ERK1/2 phosphorylation (Figure 6B). These results suggest that sE-selectin mediates its signal
in HMVECs through PI3K/Akt and ERK1/2 pathways via Src kinases. HMVECs
transfected with antisense Src ODNs showed significant inhibition of
sE-selectin-meditated Src phosphorylation compared with sense Src ODNs
(Figure 6C). HMVECs transfected with dominant-negative mutants
of Akt and ERK1/2 showed similar relative transfection efficiency as
assessed by Western blotting with the tagged protein hemagglutinin (HA)
(Figure 6D).
The Src inhibitor (PP2) and the PI3K inhibitor (LY294002) inhibit sE-selectin-mediated tube formation in the Matrigel assay in vitro We performed 2 assays to examine the signaling pathways involved in sE-selectin-mediated angiogenesis. In the first assay, the Matrigel in vitro HMVEC tube formation assay, we used PP2, LY294002, and PD98059 inhibitors to study the role of Src kinases, PI3K, and MAPK, respectively. The Src kinase inhibitor (PP2) and the PI3K inhibitor (LY294002) significantly inhibited sE-selectin-mediated HMVEC tube formation (47% and 49%, respectively) in the Matrigel in vitro assay (P < .05; Figure 7). However, the MAPK inhibitor (PD98059) failed to show significant inhibition of HMVEC tube formation (5%) compared with sE-selectin-treated cells. The same assay was performed using HMVECs transfected with Akt or ERK1/2 dominant-negative mutants or with HMVECs transfected with Src sense or antisense ODNs. HMVECs transfected with pcDNA3 plasmids containing no insert were used as the negative control (Figure 8). Similar to the inhibitor studies, HMVECs transfected with the Src antisense ODNs or Akt dominant-negative mutants showed significant inhibition of sE-selectin-mediated tube formation, whereas HMVECs transfected with ERK1/2 mutants or Src sense ODNs did not show significant inhibition. These results suggest that sE-selectin mediates HMVEC tube formation in Matrigel in vitro through the Src and PI3K pathways but not through the MAPK pathway.
sE-selectin mediates blood vessel formation through Src and PI3 kinase pathways We used a bioassay, the Matrigel-plug in vivo assay, to examine whether sE-selectin mediates its biologic function through similar signaling pathways as observed in HMVEC tube formation by the Matrigel in vitro assay. Each inhibitor (PP2, LY294002, or PD98059) was incorporated in the Matrigel along with sE-selectin before Matrigel was injected into the mice. Similar to the results observed with the in vitro HMVEC tube formation assay, PP2 and LY294002 significantly (P < .05) inhibited sE-selectin-mediated blood vessel formation (65% and 44%, respectively) in the Matrigel in vivo assay (Figure 9). However, the MAPK inhibitor PD98059 did not show significant inhibition of sE-selectin-mediated blood vessel formation (8%). In the same assay system, the MAPK inhibitor PD98059 significantly inhibited bFGF-mediated blood vessel formation (Figure 9C). These results along with the in vitro tube formation assay as well as HMVEC chemotaxis assay suggest that that sE-selectin mediates its biologic function in HMVECs predominantly through Src and PI3K pathways.
In the present study, we have examined the role of different signaling pathways by which sE-selectin mediates HMVEC chemotaxis and angiogenesis. We have previously shown that sE-selectin is a potent angiogenic mediator,16 and sE-selectin levels are up-regulated in patients with vasculoproliferative disorders such as RA25 and tumor growth.14,15 However, the signaling pathways by which sE-selectin mediates HMVEC chemotaxis and angiogenesis are still unknown. Our results from the present study show that sE-selectin mediates HMVEC chemotaxis and angiogenesis predominantly through the Src and PI3K pathways. Previously, Simon et al26 have shown that neutrophil tethering on intact transmembrane E-selectin transduces signals in endothelial cells through the MAPK signaling pathway, and cross-linking of endothelial cell-surface E-selectin with antibodies led to up-regulation of mRNA for c-fos, an early response gene, through the Ras-MAPK pathway.27 We have recently shown that sE-selectin is a potent chemotactic factor for monocytes, and it mediates monocyte chemotaxis through the Src-MAPK pathway.17 However, to our knowledge this is the first report studying the signaling cascade involved in soluble E-selectin-mediated endothelial cell chemotaxis and angiogenesis. HMVECs stimulated with sE-selectin showed phosphorylation of a number of proteins corresponding to molecular weights of 140 to 150, 130 to 140, 55 to 65, and 30 to 40 kDa (data not shown). As the predominant band obtained using anti-phosphotyrosine antibody was observed in the molecular-weight range of Src kinase, and the Src family kinases are known to play an important role in a number of physiologic functions including monocyte adherence to endothelial cells,28 endothelial cell differentiation,29 endothelial cell survival,30 and endothelial cell proliferation and angiogenesis,1 we examined the role of Src kinase in sE-selectin-stimulated HMVECs. sE-selectin induced a marked increase in HMVEC Src kinase phosphorylation, which was substantially inhibited by PP2 or by transfecting the HMVECs with Src antisense ODNs, thus indicating that Src may be an important mediator in sE-selectin-induced signaling in HMVECs. We have previously shown in monocytes that sE-selectin activates ERK1/2 and p38 MAPK pathways downstream of Src kinase.17 We next examined whether sE-selectin also activates ERK1/2 and p38 MAPK in HMVECs. sE-selectin induced a time-dependent increase in ERK1/2 phosphorylation, which was significantly inhibited by PP2. However, sE-selectin failed to activate p38 MAPK in HMVECs. These results suggest that sE-selectin may be using similar signaling pathways in HMVECs as observed previously in monocytes,17 except that in HMVECs sE-selectin does not activate p38 MAPK. PI3K, a heterodimer of an 85-kDa adaptor subunit and 100-kDa catalytic subunit,31,32 is activated by a number of growth factors including VEGF, FGF, platelet-derived growth factor (PDGF), and EGF.24,33 It has been implicated in the regulation of cell proliferation,24 differentiation,34 cell survival,35 and angiogenesis.2 To test whether sE-selectin also mediates its signal in HMVECs through PI3K, we examined the activation of PI3K by studying the phosphorylation of 2 downstream PI3K substrates: phosphatidylinositol (PI) and the serine-threonine kinase Akt. sE-selectin induced markedly higher PI and Akt phosphorylation in HMVECs compared with nonstimulated cells. A number of studies have shown that PI3K and its substrate Akt can be activated by Src family kinases.1,30,36 In order to examine whether sE-selectin induces PI3K activation via Src family kinases, HMVECs were pretreated with PP2 (10 µM) for 2 hours prior to stimulation with sE-selectin. Pretreatment of HMVECs with PP2 significantly inhibited sE-selectin-mediated PI phosphorylation as well as Akt phosphorylation (50%-60%). These results indicate that sE-selectin-induced PI3K/Akt activation is mediated via Src kinase. To further understand whether there was any cross-regulation of PI3K/Akt and ERK1/2 pathways in sE-selectin-stimulated endothelial cells, HMVECs were pretreated with the ERK1/2 inhibitor (PD98059) or the PI3K inhibitor (LY294002) prior to stimulation with sE-selectin. Similar studies were done using HMVECs transfected with ERK1/2 or Akt mutants that were subsequently stimulated with sE-selectin. Our results indicate that both PI3K/Akt and ERK1/2 pathways are activated by sE-selectin in HMVECs independently of each other via Src kinase. A previous study33 has shown that EGF also uses a similar signaling cascade as observed with sE-selectin. It may be important to point out that E-selectin contains an EGF motif in its sequence.9 However, sE-selectin failed to show EGF receptor phosphorylation in endothelial cells (data not shown). It is possible that sE-selectin may be using a similar receptor molecule to mediate its signal. Currently, only the lectin-binding part of the sE-selectin receptor (sialyl Lex) is known and is present on leukocytes as well as on endothelial cells.10-12 The structure of the protein portion of the receptor molecule is unknown. Next, to examine the functional role of sE-selectin, we performed HMVEC chemotaxis assays, Matrigel in vitro HMVEC tube formation assays, and Matrigel-plug in vivo blood vessel formation assays. The results from HMVEC chemotaxis using signaling inhibitors suggest that sE-selectin mediates chemotaxis predominantly through the Src and PI3K pathways. Inhibition of the Src pathway by PP2 provided the maximum inhibition (36%), followed by the PI3K inhibitor LY294002 (33%) and MAPK inhibitor PD98059 (20%). However, none of the inhibitors completely blocked sE-selectin-mediated HMVEC chemotaxis, thereby suggesting that sE-selectin may be mediating HMVEC chemotaxis through multiple pathways. Pretreatment of HMVECs with a combination of PP2, PD98059, and LY294002 was most effective and showed 87% inhibition of sE-selectin-mediated HMVEC chemotaxis, whereas combination of PP2 plus LY294002 or PP2 plus PD98059 showed 79% and 76% inhibition, respectively. However, combination of PD98059 plus LY294002 was much less effective and showed only 46% inhibition. These results suggests that Src may also be activating other pathways that are independent of PI3K/Akt or ERK1/2 to mediate HMVEC chemotaxis as Src inhibitor PP2 is needed to mediate the most significant inhibition. To further corroborate our results using inhibitors, we performed endothelial cell chemotaxis assays using HMVECs transiently transfected with dominant-negative mutants of ERK1/2 and Akt or HMVECs transfected with Src antisense and sense ODNs. HMVECs transfected with the Akt mutant or Src antisense ODNs showed significant decrease in sE-selectin-mediated HMVEC chemotaxis (55% and 53%, respectively) compared with HMVECs transfected with control vector alone or Src sense ODNs. In contrast, HMVECs transfected with an ERK1/2 mutant did not show significant inhibition (14%). Taken together, these results from HMVEC chemotaxis assay using signaling inhibitors as well as dominant-negative mutants or Src antisense ODNs suggest that sE-selectin may be mediating HMVEC chemotaxis predominantly through the Src and PI3K pathways, and partially through the ERK1/2 MAPK pathway. Abu-Ghazaleh et al37 and Mochizuki et al38 have also shown that Src and PI3K pathways play a predominant role in the endothelial cell migration in response to VEGF and angiopoietin 2. Angiogenesis is critical in the development of tumors2 and
inflammatory disorders such as RA.39,40 We have previously reported that sE-selectin is a potent angiogenic
mediator.16 In the present study we examined the signaling
cascade by which sE-selectin mediates angiogenesis. We used 2 assays to
study angiogenesis, the Matrigel in vitro HMVEC tube formation assay
and Matrigel-plug in vivo assay. sE-selectin induced a 2.2-fold
increase in endothelial cell tube formation compared with vehicle
control. PP2 and LY294002 significantly (P < .05)
inhibited sE-selectin-mediated endothelial cell tube formation (47%
and 49%, respectively). Similarly, HMVECs transfected with Src
antisense ODNs or Akt dominant-negative mutants showed significant
inhibition of sE-selectin-mediated tube formation compared with HMVECs
transfected with control plasmids or Src sense ODNs. However, HMVECs
transfected with an ERK1/2 mutant or treated with an ERK1/2 inhibitor
(PD98059) failed to show significant inhibition. In the Matrigel in
vivo assay, sE-selectin also induced significant (2.2-fold) increase in
blood vessel formation, which was significantly inhibited
(P < .05) by treatment with PP2 (65%) or LY294002
(44%). Similar to these results obtained in the Matrigel in vitro tube
formation assay, treatment with PD98059 failed to significantly inhibit
sE-selectin-mediated blood vessel formation in Matrigel plugs in vivo
(8%). These results suggest that even though the MAPK pathway is
activated by sE-selectin in HMVECs and might play a partial role in
sE-selectin-mediated HMVEC chemotaxis, sE-selectin-mediated blood
vessel formation both in vitro as well as in vivo is predominantly
mediated through the Src and PI3K pathways. Previously, Hartwell et
al41 have shown that E-selectin-deficient and wild-type
mice exhibit similar blood vessel formation in response to
bFGF and tumor necrosis factor-
Submitted April 29, 2002; accepted January 3, 2003.
Prepublished online as Blood First Edition Paper, January 9, 2003; DOI 10.1182/blood-2002-04-1237.
Supported by the Gallagher Professorship for Arthritis Research and funds from the Veterans' Administration Research Service. Additional support included funds from National Institute of Health grants AI-40987 and HL-58695.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Alisa E. Koch, Department of Medicine, Division of Rheumatology, Northwestern Medical School, 303 E Chicago Ave, Ward 3-315, Chicago, IL 60611; e-mail: ae-koch{at}northwestern.edu.
1. Eliceiri BP, Paul R, Schwartzberg PL, et al. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell. 1999;4:915-924[CrossRef][Medline] [Order article via Infotrieve].
2.
Jiang BH, Zheng JZ, Aoki M, et al.
Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells.
Proc Natl Acad Sci U S A.
2000;97:1749-1753 3. Kypta RM, Goldberg Y, Ulug ET, et al. Association between the PDGF receptor and members of the src family of tyrosine kinases. Cell. 1990;62:481-492[CrossRef][Medline] [Order article via Infotrieve]. 4. Mori S, Ronnstrand L, Yokote K, et al. Identification of two juxtamembrane autophosphorylation sites in the PDGF beta-receptor; involvement in the interaction with Src family tyrosine kinases. EMBO J. 1993;12:2257-2264[Medline] [Order article via Infotrieve]. 5. Toker A, Cantley LC. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature. 1997;387:673-676[CrossRef][Medline] [Order article via Infotrieve].
6.
Cardone MH, Roy N, Stennicke HR, et al.
Regulation of cell death protease caspase-9 by phosphorylation.
Science.
1998;282:1318-1321
7.
Carlos TM, Harlan JM.
Leukocyte-endothelial adhesion molecules.
Blood.
1994;84:2068-2101
8.
Bevilacqua MP, Pober JS, Mendrick DL, et al.
Identification of an inducible endothelial-leukocyte adhesion molecule.
Proc Natl Acad Sci U S A.
1987;84:9238-9242
9.
Chapman PT, Haskard DO.
Leukocyte adhesion molecules.
Br Med Bull.
1995;51:296-311
10.
Phillips ML, Nudelman E, Gaeta FCA, et al.
ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex.
Science.
1990;250:1130-1132 11. Lowe JB, Stoolman LM, Nair RP, et al. ELAM-1-dependent cell adhesion to vascular endothelium determined by a transfected human fucosyltransferase cDNA. Cell. 1990;63:475-484[CrossRef][Medline] [Order article via Infotrieve].
12.
Berg EL, Robinson MK, Mansson O, et al.
A carbohydrate domain common to both sialyl-Lea and sialyl-Lex is recognized by the endothelial cell leukocyte adhesion molecule ELAM-1.
J Biol Chem.
1991;266:14869-14872 13. Koch AE, Turkiewicz W, Harlow LA, et al. Soluble E-selectin in arthritis. Clin Immunol Immunopathol. 1993;69:29-35[CrossRef][Medline] [Order article via Infotrieve]. 14. Hebbar M, Peyrat JP. Significance of soluble endothelial molecule E-selectin in patients with breast cancer. Int J Biol Markers. 2000;15:15-21[Medline] [Order article via Infotrieve]. 15. Benekli M, Gullu IH, Tekuzman G, et al. Circulating intercellular adhesion molecule-1 and E-selectin levels in gastric cancer. Br J Cancer. 1998;78:267-271[Medline] [Order article via Infotrieve]. 16. Koch AE, Halloran MM, Haskell CJ, et al. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature. 1995;376:517-519[CrossRef][Medline] [Order article via Infotrieve].
17.
Kumar P, Hosaka S, Koch AE.
Soluble E-selectin induces monocyte chemotaxis through Src family tyrosine kinases.
J Biol Chem.
2001;276:21039-21045
18.
Morel JC, Park CC, Zhu K, Kumar P, Ruth JH, Koch AE.
Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression.
J Biol Chem.
2002;277:34679-34691 19. Volin MV, Harlow LA, Woods JM, et al. Treatment with sulfasalazine or sulfapyridine, but not 5-aminosalicyclic acid, inhibits basic fibroblast growth factor-induced endothelial cell chemotaxis. Arthritis Rheum. 1999;42:1927-1935[CrossRef][Medline] [Order article via Infotrieve]. 20. Passaniti A, Taylor RM, Pili R, et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest. 1992;67:519-528[Medline] [Order article via Infotrieve]. 21. Johns A, Freay AD, Fraser W, et al. Disruption of estrogen receptor gene prevents 17 beta estradiol-induced angiogenesis in transgenic mice. Endocrinology. 1996;137:4511-4513[Abstract].
22.
Lijana RC, Williams MC.
Tetramethylbenzidine 23. Liem HH, Cardenas F, Tavassoli M, et al. Quantitative determination of hemoglobin and cytochemical staining for peroxidase using 3,3',5,5'-tetramethylbenzidine dihydrochloride, a safe substitute for benzidine. Anal Biochem. 1979;98:388-393[CrossRef][Medline] [Order article via Infotrieve].
24.
Roche S, Koegl M, Courtneidge SA.
The phosphatidylinositol 3-kinase alpha is required for DNA synthesis induced by some, but not all, growth factors.
Proc Natl Acad Sci U S A.
1994;91:9185-9189
25.
Jacob CO, McDevitt HO.
Tumour necrosis factor-
26.
Simon SI, Hu Y, Vestweber D, et al.
Neutrophil tethering on E-selectin activates beta 2 integrin binding to ICAM-1 through a mitogen-activated protein kinase signal transduction pathway.
J Immunol.
2000;164:4348-4358
27.
Hu Y, Kiely JM, Szente BE, et al.
E-selectin-dependent signaling via the mitogen-activated protein kinase pathway in vascular endothelial cells.
J Immunol.
2000;165:2142-2148 28. Chisholm LJ, Dovgan PS, Agrawal DK, et al. Modulation of monocyte adherence to endothelial cells by endothelin-1 involvement of Src (p60src) and JAK1-like kinases. J Vasc Surg. 1996;23:288-300[CrossRef][Medline] [Order article via Infotrieve]. 29. Klint P, Kanda S, Kloog Y, et al. Contribution of Src and Ras pathways in FGF-2 induced endothelial cell differentiation. Oncogene. 1999;18:3354-3364[CrossRef][Medline] [Order article via Infotrieve]. 30. Wong BR, Besser D, Kim N, et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell. 1999;4:1041-1049[CrossRef][Medline] [Order article via Infotrieve]. 31. Hiles ID, Otsu M, Volinia S, et al. Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit. Cell. 1992;70:419-429[CrossRef][Medline] [Order article via Infotrieve].
32.
Klippel A, Escobedo JA, Hu Q, et al.
A region of the 85-kilodalton (kDa) subunit of phosphatidylinositol 3-kinase binds the 110-kDa catalytic subunit in vivo.
Mol Cell Biol.
1993;13:5560-5566
33.
Thakker GD, Hajjar DP, Muller WA, et al.
The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling.
J Biol Chem.
1999;274:10002-10007
34.
Qiu Y, Robinson D, Pretlow TG, et al.
Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells.
Proc Natl Acad Sci U S A.
1998;95:3644-3649
35.
Yao R, Cooper GM.
Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor.
Science.
1995;267:2003-2006
36.
Vara JA, Caceres MA, Silva A, et al.
Src family kinases are required for prolactin induction of cell proliferation.
Mol Biol Cell.
2001;12:2171-2183 37. Abu-Ghazaleh R, Kabir J, Jia H, et al. Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and anti-apoptosis in endothelial cells. Biochem J. 2001;360:255-264[CrossRef][Medline] [Order article via Infotrieve].
38.
Mochizuki Y, Nakamura T, Kanetake H, et al.
Angiopoietin 2 stimulates migration and tube-like structure formation of murine brain capillary endothelial cells through c-Fes and c-Fyn.
J Cell Sci.
2002;115:175-183
39.
Park CC, Morel JC, Amin MA, et al.
Evidence of IL-18 as a novel angiogenic mediator.
J Immunol.
2001;167:1644-1653 40. Koch AE. The role of angiogenesis in rheumatoid arthritis: recent developments. Ann Rheum Dis. 2000;59:165-171. 41. Hartwell DW, Butterfield CE, Frenette PS, et al. Angiogenesis in P- and E-selectin-deficient mice. Microcirculation. 1998;5:173-178[CrossRef][Medline] [Order article via Infotrieve]. 42. Aoki M, Kanamori M, Yudoh K, et al. Effects of vascular endothelial growth factor and E-selectin on angiogenesis in the murine metastatic RCT sarcoma. Tumour Biol. 2001;22:239-246[CrossRef][Medline] [Order article via Infotrieve].
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  V. W.M. van Hinsbergh and P. Koolwijk Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead Cardiovasc Res, May 1, 2008; 78(2): 203 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dimmeler Novel player in cell recruitment Blood, December 1, 2007; 110(12): 3821 - 3822. [Full Text] [PDF]
|
|
|
|
|
|
I.-Y. Oh, C.-H. Yoon, J. Hur, J.-H. Kim, T.-Y. Kim, C.-S. Lee, K.-W. Park, I.-H. Chae, B.-H. Oh, Y.-B. Park, et al. Involvement of E-selectin in recruitment of endothelial progenitor cells and angiogenesis in ischemic muscle Blood, December 1, 2007; 110(12): 3891 - 3899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Q. Werdich and J. S. Penn Specific Involvement of Src Family Kinase Activation in the Pathogenesis of Retinal Neovascularization Invest. Ophthalmol. Vis. Sci., November 1, 2006; 47(11): 5047 - 5056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Amin, C. S. Haas, K. Zhu, P. J. Mansfield, M. J. Kim, N. P. Lackowski, and A. E. Koch Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 kinase, and NF{kappa}B Blood, March 15, 2006; 107(6): 2252 - 2261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Hall, F. R. Westwood, and P. F. Wadsworth Review of the Effects of Anti-Angiogenic Compounds on the Epiphyseal Growth Plate Toxicol Pathol, February 1, 2006; 34(2): 131 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Koshida, P. Rocic, S. Saito, T. Kiyooka, C. Zhang, and W. M. Chilian Role of Focal Adhesion Kinase in Flow-Induced Dilation of Coronary Arterioles Arterioscler Thromb Vasc Biol, December 1, 2005; 25(12): 2548 - 2553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Gruemmer, L Klein-Hitpass, and J Neulen Regulation of gene expression in endothelial cells: the role of human follicular fluid J. Mol. Endocrinol., February 1, 2005; 34(1): 37 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kumar, A. I. Miller, and P. J. Polverini p38 MAPK Mediates {gamma}-Irradiation-induced Endothelial Cell Apoptosis, and Vascular Endothelial Growth Factor Protects Endothelial Cells through the Phosphoinositide 3-Kinase-Akt-Bcl-2 Pathway J. Biol. Chem., October 8, 2004; 279(41): 43352 - 43360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. H. Lo and Y. H. Wong Signal Transducer and Activator of Transcription 3 Activation by the {delta}-Opioid Receptor via G{alpha}14 Involves Multiple Intermediates Mol. Pharmacol., June 1, 2004; 65(6): 1427 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yu, K. S. Moulton, M. K. Khan, S. Vineberg, E. Boye, V. M. Davis, P. E. O'Donnell, J. Bischoff, and D. S. Milstone E-selectin is required for the antiangiogenic activity of endostatin PNAS, May 25, 2004; 101(21): 8005 - 8010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A E Koch Angiogenesis as a target in rheumatoid arthritis Ann Rheum Dis, November 1, 2003; 62(90002): ii60 - 67. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
(TNF-
a substitute for benzidine in hemoglobin analysis.
J Lab Clin Med.
1979;94:266-276